Protein delivery in intermittent and continuous enteral nutrition with a protein-rich formula in critically ill patients-a protocol for the prospective randomized controlled proof-of-concept Protein Bolus Nutrition (Pro BoNo) study.
Adult intensive and critical care
Nutrition and dietetics
Ultrasound
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Aug 2020
25 Aug 2020
Historique:
received:
20
01
2020
accepted:
27
07
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Critically ill patients rapidly develop muscle wasting resulting in sarcopenia, long-term disability and higher mortality. Bolus nutrition (30-60 min period), whilst having a similar incidence of aspiration as continuous feeding, seems to provide metabolic benefits through increased muscle protein synthesis due to higher leucine peaks. To date, clinical evidence on achievement of nutritional goals and influence of bolus nutrition on skeletal muscle metabolism in ICU patients is lacking. The aim of the Pro BoNo study (Protein Bolus Nutrition) is to compare intermittent and continuous enteral feeding with a specific high-protein formula. We hypothesise that target quantity of protein is reached earlier (within 36 h) by an intermittent feeding protocol with a favourable influence on muscle protein synthesis. Pro BoNo is a prospective randomised controlled study aiming to compare the impact of intermittent and continuous enteral feeding on preventing muscle wasting in 60 critically ill patients recruited during the first 48 h after ICU admission. The primary outcome measure is the time until the daily protein target (≥ 1.5 g protein/kg bodyweight/24 h) is achieved. Secondary outcome measures include tolerance of enteral feeding and evolution of glucose, urea and IGF-1. Ultrasound and muscle biopsy of the quadriceps will be performed. The Basel Pro BoNo study aims to collect innovative data on the effect of intermittent enteral feeding of critically ill patients on muscle wasting. ClinicalTrials.gov NCT03587870 . Registered on July 16, 2018. Swiss National Clinical Trials Portal SNCTP000003234. Last updated on July 24, 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Critically ill patients rapidly develop muscle wasting resulting in sarcopenia, long-term disability and higher mortality. Bolus nutrition (30-60 min period), whilst having a similar incidence of aspiration as continuous feeding, seems to provide metabolic benefits through increased muscle protein synthesis due to higher leucine peaks. To date, clinical evidence on achievement of nutritional goals and influence of bolus nutrition on skeletal muscle metabolism in ICU patients is lacking. The aim of the Pro BoNo study (Protein Bolus Nutrition) is to compare intermittent and continuous enteral feeding with a specific high-protein formula. We hypothesise that target quantity of protein is reached earlier (within 36 h) by an intermittent feeding protocol with a favourable influence on muscle protein synthesis.
METHODS
METHODS
Pro BoNo is a prospective randomised controlled study aiming to compare the impact of intermittent and continuous enteral feeding on preventing muscle wasting in 60 critically ill patients recruited during the first 48 h after ICU admission. The primary outcome measure is the time until the daily protein target (≥ 1.5 g protein/kg bodyweight/24 h) is achieved. Secondary outcome measures include tolerance of enteral feeding and evolution of glucose, urea and IGF-1. Ultrasound and muscle biopsy of the quadriceps will be performed.
DISCUSSION
CONCLUSIONS
The Basel Pro BoNo study aims to collect innovative data on the effect of intermittent enteral feeding of critically ill patients on muscle wasting.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03587870 . Registered on July 16, 2018. Swiss National Clinical Trials Portal SNCTP000003234. Last updated on July 24, 2019.
Identifiants
pubmed: 32843075
doi: 10.1186/s13063-020-04635-1
pii: 10.1186/s13063-020-04635-1
pmc: PMC7449093
doi:
Substances chimiques
Dietary Proteins
0
Banques de données
ClinicalTrials.gov
['NCT03587870']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
740Subventions
Organisme : Goldschmidt & Jacobson Foundation
ID : NA
Références
J Nutr. 2011 Dec;141(12):2152-8
pubmed: 22013195
Am J Clin Nutr. 2018 Oct 1;108(4):830-841
pubmed: 30239549
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Nutr Clin Pract. 2017 Apr;32(1_suppl):58S-71S
pubmed: 28388372
Br J Nutr. 2012 Sep 28;108(6):958-62
pubmed: 22289570
Nutr Clin Pract. 2002 Apr;17(2):118-22
pubmed: 16214974
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E381-7
pubmed: 16507602
Clin Chest Med. 2015 Sep;36(3):409-18
pubmed: 26304278
J Trauma. 2007 Jul;63(1):57-61
pubmed: 17622869
PLoS One. 2011 Mar 31;6(3):e18090
pubmed: 21483870
JPEN J Parenter Enteral Nutr. 2017 Feb;41(2):171-180
pubmed: 26962061
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Nutr. 2019 Feb;38(1):48-79
pubmed: 30348463
Crit Care Med. 2015 Aug;43(8):1603-11
pubmed: 25882765
Am J Clin Nutr. 2010 Nov;92(5):1080-8
pubmed: 20844073
Am J Respir Crit Care Med. 2017 Jan 1;195(1):136-138
pubmed: 28035857
Clin Nutr. 2004 Apr;23(2):273-80
pubmed: 15030968
Curr Opin Clin Nutr Metab Care. 2018 Mar;21(2):116-120
pubmed: 29232262
Rev Hosp Clin Fac Med Sao Paulo. 2003 Jan-Feb;58(1):9-14
pubmed: 12754584
Nutr Clin Pract. 2019 Oct;34(5):735-750
pubmed: 30588654
Respir Care. 2012 Jun;57(6):958-77; discussion 977-8
pubmed: 22663970
Nutr Clin Pract. 2006 Dec;21(6):587-604
pubmed: 17119165
Nutr Clin Pract. 2018 Dec;33(6):790-795
pubmed: 29924423
J Physiol. 2001 Apr 15;532(Pt 2):575-9
pubmed: 11306673
Diabetologia. 2016 Jan;59(1):44-55
pubmed: 26404065
JPEN J Parenter Enteral Nutr. 1981 Jan-Feb;5(1):73-5
pubmed: 6785478
Intensive Care Med. 2017 Mar;43(3):380-398
pubmed: 28168570
BMC Med Imaging. 2012 Apr 02;12:7
pubmed: 22471726
J Physiol. 2011 Aug 1;589(Pt 15):3883-95
pubmed: 21669975
J Rehabil Med. 2008 Mar;40(3):185-9
pubmed: 18292919
Adv Exp Med Biol. 2018;1088:483-495
pubmed: 30390266
JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211
pubmed: 26773077
Pediatr Res. 2011 Sep;70(3):253-60
pubmed: 21654549
Clin Nutr. 2014 Dec;33(6):929-36
pubmed: 24814383
Curr Opin Clin Nutr Metab Care. 2017 Sep;20(5):390-395
pubmed: 28650855
Ann Surg. 2016 Mar;263(3):450-7
pubmed: 25549202
J Crit Care. 2018 Oct;47:324-330
pubmed: 30224027
Dis Model Mech. 2015 Sep;8(9):1059-69
pubmed: 26092121
Autophagy. 2020 Feb;16(2):271-288
pubmed: 31007149
Intensive Care Med. 2015 Mar;41(3):562-3
pubmed: 25631814
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
J Crit Care. 2015 Oct;30(5):1151.e9-14
pubmed: 26211979
JPEN J Parenter Enteral Nutr. 2018 Sep;42(7):1112-1122
pubmed: 29603281
Am J Clin Nutr. 2011 May;93(5):997-1005
pubmed: 21367943
Am J Physiol Cell Physiol. 2017 Jun 1;312(6):C724-C732
pubmed: 28356270
Crit Care. 2015 Aug 05;19:274
pubmed: 26242743
Ann Intensive Care. 2015 Dec;5(1):51
pubmed: 26055186
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
Int J Crit Illn Inj Sci. 2016 Jan-Mar;6(1):9-15
pubmed: 27051616
Nutr Clin Pract. 2017 Apr;32(1_suppl):142S-151S
pubmed: 28388374
Aust Crit Care. 2014 Nov;27(4):188-93
pubmed: 24508516
Thorax. 2009 May;64(5):418-23
pubmed: 19158125
Adv Nutr. 2017 Jul 14;8(4):624-634
pubmed: 28710148
JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):886-90
pubmed: 23980134